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Abstract The role of beta-adrenergic receptor antagonists in cardiovascular therapy has been the 
subject of various studies over time, these agents representing one of the oldest class of 
drugs used for the treatment of cardiovascular diseases. Although beta-blockers have been 
excluded from guidelines as the first-line therapy in essential hypertension, they remain 
the first choice in patients with heart failure, coronary artery disease, and atrial fibrillation. 
In this article, we review the major clinical evidence for the use of beta-blockers in 
cardiovascular diseases. 
Several trials have demonstrated that beta-blockers reduce mortality in patients with 
heart failure with a reduced ejection fraction. Also, beta-blockers have beneficial 
properties in patients with heart failure with preserved ejection fraction. Guidelines 
recommend beta-blockers for the relief of symptoms in cases of angina pectoris and for 
the control of the ventricular rate in cases of atrial fibrillation.  Also, beta-blockers have 
numerous benefits in hypertensive patients with diabetes mellitus. In conclusion, beta-
blockers are an important class of cardiovascular drugs, reducing the mortality and 
morbidity rates in patients with cardiovascular diseases. 
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Highlights ✓ Beta-adrenoreceptor antagonists (beta-blockers) are an important class of cardiovascular 
medications, used for decades in patients with arterial hypertension, chronic heart failure, 
and coronary artery disease, representing the cornerstone therapy. 
✓ Guidelines recommend beta-blockers for the relief of symptoms in cases of angina pectoris 
and in the control of the ventricular rate in cases of atrial fibrillation. 
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Introduction 
Beta-adrenoreceptor antagonists (beta-blockers) are an 
important class of cardiovascular medication, used for 
decades in patients with arterial hypertension, chronic heart 
failure, and coronary artery disease, representing the 
cornerstone therapy in these cases (1). Studies have 
consistently demonstrated that agents such as bisoprolol, 
carvedilol, and metoprolol reduce hospitalizations in 
patients diagnosed with heart failure NYHA functional 
class II to IV (2). Beta-blockers also represent the first-line 
therapy in patients with hypertension associated with heart 
failure and/or coronary artery disease (3).   
Discussions 
Mechanisms of action 
Beta-adrenoreceptor antagonists reduce the activity 
of the sympathetic nervous system through the blockade of 
beta-receptors, such as beta1-, beta2- and beta3 receptors 
(1) (Table 1).  
Beta1–adrenergic receptors are found preferentially 
in the heart and the renal juxtaglomerular apparatus. Beta1-
receptors have less influence on vascular muscles (4). The 
blockade of this subtype of beta-receptors results in 
bradycardia and increased diastolic coronary filling time, 
with reduced heart oxygen requirement. These effects are 
beneficial in cases of heart failure and myocardial ischemia 
(5). Bisoprolol and nebivolol are the agents with the 
highest beta1 selectivity effect (3).  
Beta2-adrenergic receptors are found in the smooth 
muscles of the blood vessels, their stimulation resulting in 
vasodilation (6).  
Beta3-adrenergic receptors are localized in the heart 
and adipocytes, their blockade with nonselective beta-
receptor antagonists result in weight gain and other 
metabolic effects, such as hyperglycemia (5).  
Cardioselectivity, or beta1- and beta2- receptor 
selectivity, is the characteristic of beta-receptor antagonists 
to block beta1 or beta 2 adrenergic receptors preferentially. 
Atenolol and bisoprolol are cardioselective beta-blockers, 
having an affinity for beta1-adrenergic receptors (7). These 
subtypes of beta1-receptors are associated with reduced 
cardiac output and also with reduced heart rate and 
contractility (6). The Medical Research Council for the 
treatment of hypertension in the elderly conducted a 
randomized trial which enrolled 4,396 hypertensive 
patients treated with atenolol. In this trial, atenolol was 
associated with a significant reduction in cardiovascular 
events over a period of 5 years (8).  
The Metoprolol Atherosclerosis Prevention in 
Hypertensives (MAPHY) study was a trial on 3,234 
hypertensive patients investigating the effects of 
metoprolol in reducing cardiovascular complications of 
hypertension compared to thiazide diuretics. Patients who 
received metoprolol had a lower risk of experiencing 
cardiovascular events, compared to patients treated with a 
thiazide diuretic (9). 
Table 1. Classification of beta-blockers (2) 
Non-selective 
beta-blockers  
(both beta1- and 
beta 2- receptor 
antagonism) 
Propranolol 
Carvedilol (with additional alfa1-
receptor blocking activity) 
Labetalol (with additional alfa1-













The third generation of beta-receptor antagonists, 
such as carvedilol, labetalol, and nebivolol, have 
vasodilating effects (10). Carvedilol and labetalol have 
vasodilating effects through the association of alpha-
receptor blockade and the result is represented by a 
decreased peripheral vascular resistance (3). These 
vasodilating properties are associated with other effects 
such as decreased ventricular preload and afterload (6).  
Messerli et al. noticed that beta-blockers are 
associated with metabolic disorders, such as weight gain 
and an increased incidence of new-onset diabetes (11). In 
2007, in a meta-analysis which included 94,492 patients 
treated with beta-blockers, Bangalore et al demonstrated 
that beta-receptor antagonists are associated with low 
insulin sensitivity, 22% of patients treated with beta-
blockers being diagnosed with new-onset diabetes (12).  
In 2009, Manrique et al. also reported that beta-
blockers are associated with erectile dysfunctions in up to 
20% of the patients treated with beta-blockers (13). 
Beta-blockers in heart failure 
The administration of beta-blockers is recommended 
in patients with heart failure, these agents being associated 
with lower mortality and morbidity rates (7). Trials and 
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major studies with bisoprolol, carvedilol, and metoprolol, 
administered to patients diagnosed with heart failure, have 
revealed a decreasing incidence of mortality and morbidity 
(14).  
Heart failure is associated with arterial hypertension. 
Bui et al. concluded that 75% of heart failure cases are 
preceded by hypertension (15). In a 2011 article on this 
topic, Gheorghiade et al. highlighted the importance of the 
use of beta-blockers in heart failure (16). The authors 
confirmed that beta-blockers reduce the heart rate, have 
anti-ischemic effects, and inhibit the release of 
angiotensin-converting enzymes (ACE) (14). Also, by 
blocking the sympathetic activity, beta-blockers are 
associated with the improvement of the ventricular 
function and of the hemodynamic parameters (7).  
In 2003, a randomized trial by Nodari et al. noted that 
beta-blockers are associated with a decreased pressure in 
the pulmonary artery and improvement of the left 
ventricular ejection fraction in patients with diastolic heart 
failure (17). Moreover, the administration of beta-blockers 
to patients with heart failure for a long period of time has 
been associated with the improvement of hemodynamic 
parameters (16).  
Guidelines of the European Society of Cardiology 
(ESC) and the American Heart Association (AHA) 
recommend the administration of beta-blockers associated 
with ACE inhibitors to reduce hospitalizations in patients 
with heart failure (18). Also, in cases of patients with heart 
failure and atrial fibrillation, beta-blockers are the first-line 
treatment to control the heart rate (10). Guidelines 
recommend the use of beta-blockers to reduce mortality in 
hypertensive patients who associate myocardial infarction 
in their history (11). The ESC guidelines on peripheral 
artery disease recommend beta-blockers for patients 
diagnosed with heart failure who associate peripheral 
artery disease, because symptoms of intermittent 
claudication are not affected by beta-blockers (19). 
However, in patients with peripheral arterial disease, the 
administration of selective beta-blockers with peripheral 
vasodilator action, such as nebivolol, is preferred. Also, 
nebivolol stimulates nitric oxide synthase, resulting in 
increased levels of nitric oxide, with vasodilating effects 
(16). 
Randomized trials that investigated the effects of 
beta-blockers in heart failure demonstrated that these 
agents are associated with a decreased risk of mortality and 
hospitalizations (20).  
The Cardiac Insufficiency Bisoprolol Study (CIBIS-
II) was a randomized trial conducted in 1999 in Europe 
(21). This study enrolled 2,647 patients with heart failure 
NYHA functional class III or IV with reduced ejection 
fraction, who were treated with bisoprolol. The trial was 
interrupted early because bisoprolol demonstrated a 
significant reduction in mortality, compared to placebo. 
This trial confirmed that in patients with heart failure, beta-
blockers improve the left-ventricular function (20).  
The Carvedilol Prospective Randomized Cumulative 
Survival (COPERNICUS) was a trial performed on 2,289 
patients diagnosed with heart failure and reduced ejection 
fraction (22). This study investigated the role of carvedilol 
in patients with systolic heart failure for a period of 10 
months and observed that the use of carvedilol is associated 
with a relief of heart failure symptoms and decreased 
hospitalizations. The mortality rate in this study was 
reduced by 35% for patients treated with carvedilol (20). 
Also, the Metoprolol Randomised Intervention Trial 
in Congestive Heart Failure (MERIT-HF) was conducted 
between1997-1998 and enrolled 3,991 patients diagnosed 
with heart failure NYHA functional class III-IV (23). This 
study investigated the role of metoprolol in addition to 
standard therapy in cases of heart failure. The results 
showed that metoprolol significantly reduced the mortality 
rate (24). 
The Study on the Effects of Nebivolol Intervention on 
Outcomes and Rehospitalization in Seniors with Heart 
failure (SENIORS) enrolled 2,128 patients over 70 years 
old, diagnosed with heart failure. This trial showed that 
nebivolol is associated with reduced mortality and 
morbidity and reduced hospitalization in 14% of the cases, 
compared to placebo (25). 
The Carvedilol or Metoprolol European Trial 
(COMET) was a randomized controlled trial on 3,029 
patients that compared the benefits of carvedilol or 
metoprolol in patients with chronic heart failure. The 
investigators observed that carvedilol reduces mortality of 
cardiovascular causes, the risk of sudden cardiac death, and 
the incidence of stroke and myocardial infarction, 
compared to metoprolol (26).  
In a study by Bohm et al. in 2011, which enrolled 
patients with heart failure, it was noted that the 
administration of beta-blockers before admission to the 
hospital and after discharge was associated with lower 
mortality in patients with acute decompensation of heart 
failure (27).  
Also, in cases of patients with heart failure with 
preserved ejection fraction, the ESC and AHA guidelines 
recommend the administration of beta-blockers (28). 
Studies on this topic have demonstrated that beta-blockers 
are associated with reduced mortality in these cases (25).  
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Moreover, a meta-analysis on this topic conducted by 
Bavishi et al. in 2015 noted that beta-blockers are 
associated with reduced mortality in patients with heart 
failure (29). 
Beta-blockers in arterial hypertension and diabetes 
It is well known that hypertension is associated with 
an increased risk of heart failure, stroke, and renal disease, 
and thus, a good therapeutic control of blood pressure is 
essential (30).  
The Medical Research Council for the treatment of 
hypertension in the elderly conducted a trial on 4,396 
hypertensive patients treated with hydrochlorothiazide or 
atenolol (31). This trial found that hydrochlorothiazide is 
associated with a lower risk of cardiovascular events than 
atenolol (20). On the other hand, the Heart Attack Primary 
Prevention in Hypertension (HAPPHY) trial, performed on 
6,569 patients, compared the benefits of the use of diuretics 
versus beta-blockers in hypertensive patients. This study 
showed no additional benefits between beta-blockers 
versus thiazide diuretics in cardiovascular prognosis (32). 
Also, atenolol was compared to losartan in the 
Losartan Intervention for Endpoint Reduction (LIFE) trial, 
performed on 9,193 hypertensive patients. In this trial, the 
beneficial effects of atenolol compared to losartan in 
hypertensive patients with left ventricular hypertrophy 
were investigated, with results showing no differences 
between the two groups (33).  
Studies demonstrated that metoprolol has more 
benefits in hypertensive patients (34). The Metoprolol 
Atherosclerosis Prevention in Hypertensives (MAPHY) 
trial, which investigated the benefits of metoprolol versus 
thiazide diuretics in hypertensive patients with risk factors 
for coronary disease discovered that the treatment with 
metoprolol in these cases reduces the risk of coronary 
events. The results showed that treatment with metoprolol 
is associated with a lower incidence of cardiovascular 
events (35).  
Diabetes mellitus is associated with an increased risk 
of developing cardiovascular diseases and the association 
with hypertension doubles the risk. In patients with 
diabetes mellitus, the risk of heart diseases is two times 
higher compared to patients without diabetes (36).  
  The ESC and AHA guidelines recommend all 
classes of antihypertensive therapy in hypertensive patients 
who associate diabetes mellitus. Also, beta-blockers are 
recommended in diabetic patients with acute myocardial 
infarction (29). In diabetic patients with prior myocardial 
infarction, beta-blockers reduce the incidence of 
arrhythmias, sudden cardiac death, and the recurrence of 
cardiac ischemic events (37). Kjekshus et al. discovered 
that diabetic patients treated with beta-blockers have a 10% 
mortality rate compared to 23% in patients who are not 
receiving beta-blockers (38). Guidelines recommend the 
use of beta-blockers in patients with diabetes and heart 
failure to reduce hospitalization and mortality (36).  
Although beta-blockers have negative metabolic 
effects, with increased insulin resistance, guidelines 
recommend the administration of beta-blockers in diabetic 
patients because the adverse metabolic effects are fewer 
than the benefits in these cases (39). Trials on this issue 
found that a good control of hypertension is more 
important in these patients, having macrovascular and 
microvascular benefits (40). The UK Prospective Diabetes 
Study investigated the effects of blood pressure control in 
hypertensive patients who associate diabetes, after 9 years 
of follow-up. In this study, the administration of atenolol 
was associated with a lower risk of microvascular and 
macrovascular complications in 32% of the cases (41). 
Beta-blockers and coronary artery disease 
Beta-blockers represent the main class of drugs in 
patients with coronary artery disease, having multiple 
benefits. The effects of beta-blockers in these cases are 
based on their negative inotropic and chronotropic 
properties. Beta-blockers reduce heart rate, contractility, 
and systolic blood pressure, resulting in reduced 
myocardial oxygen requirements. Also, beta-blockers 
prolong the diastolic filling time, with improved coronary 
perfusion (42). Beta-blockers increase the perfusion of the 
hibernating ischemic myocardial areas and reduce the 
myocardial wall stress, with a low risk of myocardial 
rupture after acute myocardial infarction (38, 43).  
In patients diagnosed with angina pectoris, beta-
blockers are the essential treatment, reducing the 
symptoms and preventing cardiovascular events. Beta-
blockers are recommended for the control of angina 
symptoms in patients with coronary artery disease (44, 45).  
Beta-receptor antagonists are recommended in 
patients with silent ischemia and with a large area of 
ischemic myocardial tissue (42). Also, beta-blockers are 
used in cases of microvascular angina. Cardioselective 
beta1-receptor antagonists are used most frequently in 
patients diagnosed with coronary artery disease (37). 
A study performed in 2001 by Gotlieb et al., which 
enrolled 69,000 patients with prior myocardial infarction 
treated with beta-blockers, demonstrated that the use of 
beta-receptor antagonists was associated with increased 
survival rates in 40% of the patients (46). It was noticed 
that in cases of stable angina pectoris, the use of beta-
blockers is associated with symptom relief.  
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A meta-analysis conducted by Huang et al. in 2012 
assessed the impact of beta-blockers on the mortality rate 
in cases of stable angina pectoris and concluded that 
cardioselective beta-blockers improve survival rates (47). 
Data from the literature state that beta-blockers have 
a protective role regarding the recurrence of cardiovascular 
ischemic events (48). In an analysis performed by 
Bangalore et al. in 2014, patients with prior myocardial 
infarction treated with beta-blockers were at lower risk of 
recurrent myocardial infarction, although the mortality 
rates were not improved (49).  
The COMMIT trial (ClOpidogrel and Metoprolol in 
Myocardial Infarction Trial) was a randomized trial which 
investigated the role of intravenous and oral administration 
of metoprolol in 45,852 patients with acute myocardial 
infarction from 1,250 hospitals in China, between1999-
2005 (50). This trial showed that the early use of beta-
blockers in acute myocardial infarction reduces the rates of 
re-infarction and ventricular arrhythmia, but the risk of 
cardiogenic shock remains high (49), especially in patients 
above 70 years old, with a systolic blood pressure <120 
mmHg and in patients with myocardial infarction Killip 
class III (31).  
Also, beta-blockers have beneficial effects in patients 
with acute myocardial infarction and heart failure with a 
reduced ejection fraction. CAPRICORN (CArvedilol Post-
InfaRct SurvIval COntRolled evaluatioN) was a 2001 trial 
enrolling 1,959 patients from 17 countries, with a follow-
up of 1.3 years (50). This trial investigated the effect of 
carvedilol after myocardial infarction in patients with left 
ventricular dysfunction, demonstrating that the treatment 
with carvedilol was associated with decreased mortality in 
these cases (51). 
Beta-blockers and heart rate control 
Atrial fibrillation is the most common arrhythmia in 
clinical practice and it is associated with increased risks of 
morbidity and mortality. Hypertension, ischemic 
cardiomyopathy, valvular disease, and thyroid diseases are 
risk factors for the development of atrial fibrillation (27, 
52, 53).  
Beta-adrenergic receptor antagonists are included in 
class II antiarrhythmic agents. Their benefit in atrial 
fibrillation is the ventricular rate control. They act by 
blocking the effects of catecholamine hormones on beta1-
adrenergic receptors, resulting in a decreased sympathetic 
activity of the heart. Also, beta-blockers decrease the 
atrioventricular conduction through the atrioventricular 
node (33). 
The ESC guidelines recommend that patients with 
atrial fibrillation be treated with beta-blockers in order to 
achieve ventricular rate control and to regulate the irregular 
heart rhythm (50). The oral administration of beta-blockers 
is recommended to control the ventricular rate in patients 
with persistent or permanent atrial fibrillation (54). 
Also, beta-blockers are recommended for the 
prevention of atrial fibrillation in patients with 
hypertrophic cardiomyopathy. The AHA guidelines 
recommend the use of beta-blockers to control the 
ventricular rate in patients with heart failure and acute 
coronary syndrome, without high risks of cardiogenic 
shock (55). 
The AFFIRM trial (the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management) was a multicenter 
trial, which enrolled 4,060 patients diagnosed with non-
valvular atrial fibrillation (56). This trial compared rate-
control and rhythm-control strategies for the treatment of 
atrial fibrillation. The results showed that beta-blockers 
have beneficial effects for the ventricular rate control in 
70% of patients with atrial fibrillation (57). 
Conclusions 
The benefit of the use of beta-blockers in 
cardiovascular diseases has been confirmed in numerous 
trials. These trials have demonstrated that beta-blockers 
reduce mortality in patients with heart failure with a 
reduced ejection fraction. Also, beta-blockers have 
beneficial properties in patients with heart failure with 
preserved ejection fraction. Guidelines recommend beta-
blockers for the relief of symptoms in cases of angina 
pectoris and for the control of the ventricular rate in cases 
of atrial fibrillation. Also, beta-blockers have numerous 
benefits in hypertensive patients with diabetes mellitus. In 
conclusion, beta-blockers are an important class of 
cardiovascular drugs, reducing the mortality and morbidity 
rates in patients with cardiovascular diseases. 
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